PDF is available of LRG Science here.
The Importance of Biomarker Testing for the Effective Treatment of GIST Patients
Authored by LRG Patient Registry Supervisor Sahibjeet Kaur, MPH
This issue of LRG Science presents six case studies as evidence that the practice of biomarker/mutational testing early in a GIST patient’s journey is a critical path to the most effective treatment. Each patient was diagnosed with GIST, but did not receive mutational testing early enough to avoid suffering adverse side effects and wasting money on unnecessary, costly drugs.
This advanced testing not only allows patients to save time and money, but can reveal data that will indicate potential future treatment lines. Better quality of life, security about future treatments and greater overall survival make mutational testing a necessary component to the standard of care for all GIST patients.
We welcome commentary on this article and invite new submissions for 2021 and 2022. To inquire further or to submit commentary, please email Mary Garland, Director of Communications: mgarland@liferaftgroup.org
